Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for prevention of postoperative pulmonary complications
ACTRN12623000394640Phase 4Completed
- Sponsor
- University of Melbourne
- Start
- Jul 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial in postoperative respiratory complications (PRC) comparing Sugammadex with Neostigmine (2 arms). Primary endpoint: Composite of all-cause death and new pulmonary complications. Started Jul 2023; status: completed.
02
Drugs
Sugammadexneostigmine
03
Conditions
postoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ACTRN12623000394640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000394640.